Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#3068 WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE)

Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,

Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,

#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo L

Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,

Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,